PMID- 36681809
OWN - NLM
STAT- MEDLINE
DCOM- 20230124
LR  - 20230201
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Jan 21
TI  - Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for 
      treating adrenal gland metastases from liver cancer.
PG  - 73
LID - 10.1186/s12885-023-10519-9 [doi]
LID - 73
AB  - OBJECTIVE: Stereotactic Body Radiation Therapy (SBRT) has been found beneficial 
      for adrenal gland metastases (AGMs) with a high local control rate and low 
      toxicity. The role of SBRT for AGMs in patients with liver cancer has not been 
      well-discussed before. We, therefore, report our two-institution experience to 
      further elaborate on the feasibility and effectiveness of SBRT in the treatment 
      of AGMs from liver cancer. METHODS: A total of 23 liver cancer patients (19 
      males, 4 females) with 24 AGMs treated by SBRT from July 2006 to April 2021 were 
      retrospectively included in this study. Toxicity was assessed based on clinical 
      adverse events using the Common Terminology Criteria for Adverse Events (CTCAE) 
      version 5.0. The effectiveness was assessed based on local control (LC), 
      progression-free survival (PFS), and overall survival (OS), which were calculated 
      using the Kaplan-Meier method. Univariate analyses were compared by log-rank 
      test. The relevant covariates were evaluated using Cox proportional hazards 
      models. RESULTS: The median dose was 40 Gy in 5 fractions, with the corresponding 
      median biological effective dose (BED10, alpha/beta = 10 Gy) of 72 Gy. The median 
      overall follow-up time was 15.4 months (range: 4.2-70.6 months). The complete 
      response (CR), partial response (PR), stable disease (SD) and progressive disease 
      (PD) rates were 25.0%, 20.8%, 33.3%, and 20.8%, respectively. All 6 patients with 
      AGMs accompanying symptoms had varying degrees of alleviation after SBRT. The 
      0.5-, 1-year and 2-year LC rates were 87.5%, 77.8%, and 77.8%, respectively. The 
      0.5-, 1-year and 2-year OS rates were 95.5%, 66.8%, and 41.1%, respectively. The 
      treatments were all tolerated with only one patient reporting a grade-3 hepatic 
      injury. The univariate analysis concluded that only gross tumor volume 
      (GTV) < 34.5 ml (p = 0.039) was associated with a favorable LC rate. After 
      multivariate analysis, favorable predictors correlated with OS were GTV < 34.5 ml 
      (p = 0.043), systemic therapy (p = 0.017), and without additional organ 
      metastasis after SBRT (p = 0.009). CONCLUSION: Our results suggest that SBRT is a 
      safe and effective technique to treat AGM from liver cancer, especially for small 
      GTV (< 34.5ml). Moreover, the small metastatic lesion volume, fewer metastatic 
      lesions, and intervention of systemic therapy are more likely to improve OS.
CI  - (c) 2023. The Author(s).
FAU - Xu, Bichun
AU  - Xu B
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, the Navy Medical 
      University, 200433, Shanghai, China.
FAU - Zhao, Xianzhi
AU  - Zhao X
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, the Navy Medical 
      University, 200433, Shanghai, China.
FAU - Chen, Di
AU  - Chen D
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, the Navy Medical 
      University, 200433, Shanghai, China.
FAU - Zhao, Wenjuan
AU  - Zhao W
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, the Navy Medical 
      University, 200433, Shanghai, China.
FAU - Wang, Xiaoyan
AU  - Wang X
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, the Navy Medical 
      University, 200433, Shanghai, China.
FAU - Ding, Changhua
AU  - Ding C
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, the Navy Medical 
      University, 200433, Shanghai, China.
FAU - Yuan, Zhiyong
AU  - Yuan Z
AD  - Department of Radiation Oncology, Key Laboratory of Cancer Prevention and 
      Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical 
      University Cancer Institute & Hospital, National Clinical Research Center for 
      Cancer, 300060, Tianjin, China.
FAU - Zhang, Huojun
AU  - Zhang H
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, the Navy Medical 
      University, 200433, Shanghai, China. huojunzh@163.com.
LA  - eng
GR  - 2019YPT004/the First Affiliated Hospital of Navy Medical University "234 Subject 
      Climbing Program"/
PT  - Journal Article
DEP - 20230121
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Male
MH  - Female
MH  - Humans
MH  - Retrospective Studies
MH  - *Radiosurgery/methods
MH  - *Liver Neoplasms/secondary
MH  - *Adrenal Gland Neoplasms
MH  - Adrenal Glands
PMC - PMC9862519
OTO - NOTNLM
OT  - Adrenal gland metastases (AGM)
OT  - Liver cancer
OT  - Local control
OT  - Stereotactic body radiotherapy (SBRT)
OT  - Survival
COIS- The authors declare that they have no competing interests.
EDAT- 2023/01/22 06:00
MHDA- 2023/01/25 06:00
PMCR- 2023/01/21
CRDT- 2023/01/21 23:24
PHST- 2022/09/14 00:00 [received]
PHST- 2023/01/06 00:00 [accepted]
PHST- 2023/01/21 23:24 [entrez]
PHST- 2023/01/22 06:00 [pubmed]
PHST- 2023/01/25 06:00 [medline]
PHST- 2023/01/21 00:00 [pmc-release]
AID - 10.1186/s12885-023-10519-9 [pii]
AID - 10519 [pii]
AID - 10.1186/s12885-023-10519-9 [doi]
PST - epublish
SO  - BMC Cancer. 2023 Jan 21;23(1):73. doi: 10.1186/s12885-023-10519-9.